AstraZeneca PLC (AZN) stock
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $14.23B, up 4.8% from the year before. Over ten years it grew 9.0% a year on average. The highest annual figure on record is $14.23B in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.23B | +4.8% |
| FY2024 | Dec 31, 2024 | $13.58B | +24.2% |
| FY2023 | Dec 31, 2023 | $10.94B | +12.0% |
| FY2022 | Dec 31, 2022 | $9.76B | +0.3% |
| FY2021 | Dec 31, 2021 | $9.74B | +62.5% |
| FY2020 | Dec 31, 2020 | $5.99B | -1.1% |
| FY2019 | Dec 31, 2019 | $6.06B | +2.1% |
| FY2018 | Dec 31, 2018 | $5.93B | +3.0% |
| FY2017 | Dec 31, 2017 | $5.76B | -2.3% |
| FY2016 | Dec 31, 2016 | $5.89B | -1.8% |
| FY2015 | Dec 31, 2015 | $6.00B | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.05B | +59.2% |
| Q2 FY2025 | Jun 30, 2025 | $3.55B | +94.0% |
| Q2 FY2024 | Jun 30, 2024 | $3.01B | +116.6% |
| Q2 FY2023 | Jun 30, 2023 | $2.67B | +96.7% |
| Q2 FY2022 | Jun 30, 2022 | $2.55B | +86.9% |
| Q2 FY2021 | Jun 30, 2021 | $1.83B | +35.6% |
| Q2 FY2020 | Jun 30, 2020 | $1.39B | – |
| Q2 FY2019 | Jun 30, 2019 | $1.36B | – |
| Q2 FY2018 | Jun 30, 2018 | $1.36B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.35B | – |
See a number that looks wrong?